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Abstract
Background Multiple ventilatory strategies for acute
hypoxemic respiratory failure (AHRF) in children have been
advocated, including high-frequency oscillatory ventilation
(HFOV). Despite the frequent deployment of HFOV, ran-
domized controlled trials remain elusive and currently there
are no pediatric trials looking at its use. Our longitudinal
study analyzed the predictive clinical outcome of HFOV in
pediatric AHRF given disease-specific morbidity.
Methods A retrospective 8-year review on pediatric
intensive care unit admissions with AHRF ventilated by
HFOV was performed. Primary outcomes included sur-
vival, morbidity, length of stay (LOS), and factors associ-
ated with survival or mortality.
Results A total of 102 patients underwent HFOV with a
66 % overall survival rate. Survivors had a greater LOS
than nonsurvivors (p = 0.001). Mortality odds ratio (OR)
for patients without bronchiolitis was 8.19 (CI = 1.02,
65.43), and without pneumonia it was 3.07 (CI = 1.12,
8.39). A lower oxygenation index (OI) after HFOV com-
mencement and at subsequent time points analyzed pre-
dicted survival. After 24 h, mortality was associated with
an OI [ 35 [OR = 31.11 (CI = 3.25, 297.98)]. Sepsis-
related mortality was associated with a higher baseline
FiO2 (0.88 vs. 0.65), higher OI (42 vs. 22), and augmented
metabolic acidosis (pH of 7.25 vs. 7.32) evaluated 4 h on
HFOV (p \ 0.05).
Conclusion High-frequency oscillatory ventilation may
be safely utilized. It has a 66 % overall survival rate in
pediatric AHRF of various etiologies. Patients with mor-
bidity limited to the respiratory system and optimized
oxygenation indices are most likely to survive on HFOV.
Keywords Acute hypoxemic respiratory failure 
Acute respiratory distress syndrome 
High-frequency oscillatory ventilation  Sepsis
Introduction
Mortality from acute respiratory distress syndrome
(ARDS) remains high at approximately 40 %, and it is
unclear whether there has been a significant reduction in
ICU mortality over the last decade [1, 2]. The mortality in
children appears to be lower, at 10–40 % [3]. Ventilatory
strategies for ARDS continue to evolve, with emphasis on
protective lung strategy and low tidal volume ventilation
based on the landmark 2000 ARMA trial [4]. Several
modes of ventilation have been advocated, including high-
frequency oscillatory ventilation (HFOV) [5–9]. Prospec-
tive clinical trials on HFOV for ARDS have been incon-
sistent, although recent meta-analyses suggested that
HFOV may improve survival and is unlikely to cause harm
in ARDS patients [10, 11]. A multicenter pediatric
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crossover study did show that HFOV was associated with
higher mean airway pressures (Paw), improved oxygena-
tion, and a reduced need for supplemental oxygen at
30 days [12]. Furthermore, a neonatal randomized con-
trolled trial demonstrated lower mortality in very-low-
birth-weight babies managed with HFOV [13]. Our large
tertiary-care children’s hospital has been utilizing HFOV
for a decade as rescue therapy for patients with acute
hypoxemic respiratory failure (AHRF) in accordance with
a permissive ventilation protocol. Our study was under-
taken to evaluate the utilization of HFOV in AHRF and to
determine variables associated with survival and prognos-
tic indicators.
Material and Methods
IRB approval was obtained from Miller Children’s Hospi-
tal. Patients were identified through our pediatric intensive
care unit (PICU) database (VPSLLC). All patients who had
been on HFOV during an 8-year period were selected for
review. A retrospective chart review was performed on all
patients whose complete records were accessible. Inclusion
criteria were PaO2/FiO2 \200 while on mechanical venti-
lation, failure on conventional mechanical/manual ventila-
tion, and commencement of HFOV in our PICU. Exclusion
criteria included intubation and mechanical ventilation due
to fatal head injury.
The following clinical data were collected on all patients:
age, gender, past medical history, diagnosis prior to respi-
ratory failure, pediatric risk of mortality (PRISM) score
[14], length of stay (LOS), mortality, complications, cause
of death, presence of multiple-organ dysfunction syndrome
(MODS), tolerance of full enteral feeds, and transfusion of
blood products. Hemodynamic parameters (heart rate, mean
blood pressure [MAP]) and doses of vasoactive agents were
collected immediately pre-HFOV and upon initiation, at 4,
12, 24, and 72 h after initiation, and then immediately prior
to discontinuation of HFOV. Oxygenation index (OI),
PaO2/FiO2, Paw, amplitude, frequency, FiO2, PCO2, and
pH were collected pre-HFOV and upon initiation, at 4, 12,
24, and 72 h, and then immediately prior to discontinuation
of HFOV. Respiratory rate, PEEP, and PIP were collected
pre-HFOV and after transition from HFOV back to con-
ventional ventilation. MODS and sepsis were defined using
criteria from the Pediatric Sepsis Consensus [15, 16].
Pneumonia was diagnosed based on radiographic abnor-
malities, fever, and a positive respiratory culture. Individual
radiographs were not reviewed for this study. Diagnoses
from radiographs were taken from the radiologist’s report
and correlated with the primary team’s diagnoses. Patients
were diagnosed with bronchiolitis if DFA was positive for
respiratory syncytial virus (RSV) or human metapneumo-
virus (HMPV). No attempt was made to distinguish
between RSV and HMPV bronchiolitis and pneumonia.
Ventilation Guidelines
All patients on HFOV were ventilated using Sensor Medics
(Yorba Linda, CA) ventilators. 3100A ventilators were used
for all patients less than 35 kg and 3100B ventilators were
used for patients more than 35 kg. Patients started on con-
ventional ventilation were ventilated according to our per-
missive ventilation guidelines. The guidelines are to obtain
an arterial pH[7.25, SaO2[90, and PaO2[60 on less than
0.65 FiO2, PIP\35, and tidal volume 6–8 cc/kg. PEEP is
titrated to improve oxygenation. HFOV is deployed when the
permissive ventilation goals are not being met and OI [ 15.
All study patients who were transferred from conven-
tional ventilation were previously ventilated in SIMV
pressure-limited mode. Patients were started on HFOV
according to our HFOV guidelines (FiO2 = 1.0,
Paw = 3–5 cm H2O and greater than Paw on conventional
ventilation) and amplitude was adjusted to achieve ade-
quate chest movement. Bias flow of 20–40 L/min (lpm)
was used and a frequency of 5–15 Hz (cycles/s) was used
for patients under 25 kg and 3–10 Hz was used for patients
over 25 kg. Paw was adjusted to obtain rib expansion of
nine ribs on chest radiograph. Once on HFOV, the goal was
to wean the FiO2 to less than 0.65. If this goal was
accomplished successfully, the Paw was weaned as long as
permissive variables were met. Most patients were weaned
to a goal of Paw = 15–18 before attempting to transition to
conventional ventilation, as stated in the guidelines.
Statistical Analysis
Statistical analyses were performed using the SAS statis-
tical package (SAS Institute Inc., Cary, NC). Baseline
characteristics between survivors and nonsurvivors were
compared using nonparametric Wilcoxon Mann–Whitney
tests for continuous variables, and by using v2 tests or
Fisher exact tests for dichotomous variables. Logistic
regression was used to examine the relationship between
death status and age, sex, pneumonia, sepsis, bronchiolitis,
oxygen index, and past medical history of malignancy,
pulmonary disease, or cardiac disease. The covariates with
p \ 0.05 were considered significant.
Results
A total of 124 patients were identified for chart review and 14
incomplete charts were excluded. Eight patients with fatal
head injuries were excluded as their contribution to survival
686 Lung (2012) 190:685–690
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analysis could not be elucidated. Therefore, a total of 102
patients were included in the chart extraction (see Table 1).
The overall survival rate on HFOV was 66 %. There was no
difference in mortality from year to year during the years
analyzed. Thirty-nine percent of the patients had no prior
underlying medical problems. Twelve patients were only
manually ventilated before going on HFOV without a trial of
conventional ventilation due to peak pressures greater than
45 during manual ventilation. Overall, 62 patients (61 %)
were successfully treated by HFOV and transitioned back to
conventional ventilation. Three patients were deemed to
have failed HFOV and placed back on conventional venti-
lation. Five patients went on to extracorporeal membrane
oxygenation (ECMO) and two survived. Complications in
16 % of the patients included malfunction of the oscillator
(2), catheter-associated blood stream infection (1), subglot-
tic stenosis (1), unplanned extubation (1), and air leak (11).
Overall, six patients required tracheostomy after HFOV.
Disease-Specific Morbidity
Baseline demographics and clinical variables are given in
Table 2. The causes of death are listed in Table 3. Logistic
regression showed no association between survival and
mortality for the following parameters: underlying malig-
nancy, chronic lung disease (asthma or BPD), cardiac
disease, or sepsis. Fischer exact testing and univariate
analysis did show an association between bronchiolitis and
survival (p \ 0.05). The OR for dying for patients without
bronchiolitis was 8.19 (CI = 1.02, 65.43). Univariate and
v2 analyses showed an association between pneumonia and
survival (p \ 0.05). The OR for dying for patients without
pneumonia was 3.1 (CI = 1.12, 8.39). There was no dif-
ference in the median PRISM score. Survivors did have a
greater LOS (p = 0.001) than did nonsurvivors.
A total of 29 patients met diagnostic criteria for sepsis
and 15 survived. Logistic regression failed to demonstrate
sepsis as a risk factor for death on HFOV and v2 analysis
failed to demonstrate an association.
Hemodynamics
No statistical difference was noted in the median heart rate or
blood pressure immediately pre-HFOV and upon initiation,
Table 1 Baseline demographics and clinical data variables
Variables
Patients 102
Age (months) 12 (69)
Male (%) 54 (53)
PRISM 15 (15.25)
OI 25 (17.75)
Pa/FiO2 74 (43.5)
FiO2 87.6
a
Rate 32 (11)
PIP 33 (6)
PEEP 8 (2)
Paw 18 (4)
Data expressed as median and IQR (interquartile range) or total
number and (percentage). Ventilatory data is pre-HFOV
a Value is the mean
Table 2 Comparison of survivors and nonsurvivors
Clinical
characteristics
Survived
(n = 67)
Died
(n = 35)
p value
Age (months) 10 (45) 24 (128.5) 0.73
Male (number) 32 22 0.71
PRISM 14 (12.25) 15 (21.25) 0.14
Diagnosis
Sepsis 15 14 0.1
Pneumonia 26 6 0.03
Bronchiolitis 13 1 0.03
No PMH 29 11 0.29
Ventilation
Pre-HFOV (hrs) 40 (118.5) 24 (74.5) 0.21
HFOV (hrs) 97 (134.5) 22 (122) 0.65
Transfer pawa 18 (4)
Transfer OIa 10 (6.6)
High paw 25 (6.5) 32 (9) \0.01
PICU LOS 30 (28.5) 11 (17.25) \0.01
PMH past medical history
Data expressed as median and (IQR) or total number
a Transfer Paw and transfer OI are median values when changed back
to conventional ventilation from HFOV
Table 3 Summary of nonsurvivors
Diagnosis No. of
patients
Cause
of death
Sepsis/pneumonia 16 Circulatory
failure
Pneumonia 4 Hypoxia
S/p cardiac arrest 4 MODS
CHD/cardiomyopathy 3 Circulatory
failure
Malignancy 2 Hypoxia, rad.
pneumonitis
HLH 2 MODS
Idiopathic pulmonary fibrosis 2 Hypoxia
Bronchiolitis 1 Hypoxia
End-stage CF 1 Hypercarbia
S/p status post, rad. radiation, HLH hemophagocytic lymphohistio-
cytosis, MODS multiple-organ dysfunction syndrome, CF cystic
fibrosis
Lung (2012) 190:685–690 687
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at 4, 12, 24, and 72 h, and then immediately prior to dis-
continuation of HFOV. Use of epinephrine at the time of
initiation of HFOV was associated with death [p = 0.02,
OR = 2.75 (CI = 1.17, 6.50)].
Similarly, the sepsis subgroup demonstrated no differ-
ence in baseline hemodynamics, doses of vasoactive
agents, or indicators of gas exchange. However, nonsur-
vivors were characterized by a higher baseline concentra-
tion of oxygen (0.88 vs. 0.65), elevated OI (42 vs. 22), and
greater metabolic acidosis (pH of 7.25 vs. 7.32) after 4 h on
HFOV (p \ 0.05). A trend toward significance was seen
with higher epinephrine dose requirements (0.5 vs. 0.15
mcg/(kg min)) after 4 h on HFOV (p = 0.07). The differ-
ence in OI at 12 h (42 vs. 19) was also statistically sig-
nificant (p \ 0.05).
Ventilatory Data and Gas Exchange
No difference was found in the duration of ventilation prior
to HFOV. Similarly, no statistical difference was noted on
total duration of ventilation on HFOV between survivors
and nonsurvivors. No statistical difference was calculated
in baseline Paw, OI, pH, pCO2, or PaO2/FiO2. No differ-
ence was found in pH or PCO2 at any time point analyzed.
However, the median PaO2/FiO2 was greater for survivors
immediately after starting HFOV and remained greater 4,
12, 24, and 72 h on HFOV (p \ 0.05). Survivors also had a
lower OI immediately after starting HFOV and at all time
points analyzed (Table 4). They showed a significant
decrease in their OI at 12 h compared to the value at the
start of HFOV (Fig. 1). Immediately after starting HFOV,
patients with an OI [ 50 had an OR of dying of 4.03
(CI = 1.43, 11.37). After 4 h, patients with an OI [ 40 had
an OR of dying of 3.77 (CI = 1.42, 10.04), and after 24 h,
a patient with an OI [ 35 had an OR of dying of 31.11
(CI = 3.25, 297.98).
Discussion
This longitudinal analysis is the largest single-center
pediatric study on HFOV to date. The overall HFOV sur-
vival rate of 66 % is similar to that of prior reports [17–20].
The eight patients excluded because of fatal head injuries
all had recovery of lung function and were weaned off
HFOV, so the ‘‘success rate’’ could be viewed as higher if
these patients are included. We believe our permissive
ventilation guidelines are similar to those of other PICUs,
although some may utilize higher PEEP before employing
HFOV. We also recognize our unit has a bias toward early
HFOV for AHRF. Some of this comes from the difficulty
with ventilating infants with low tidal volumes when their
intrinsic respiratory rates are high. It is much easier to
increase an adult’s intrinsic rate threefold on conventional
ventilation and still have a set respiratory rate of only 30
rather than 60–100 needed in an infant.
Our first major finding is that patients with acute disease
primarily limited to the respiratory system have improved
survival and underlying chronic lung disease does not
adversely affect outcome. A single previous study attributed
the success of HFOV in bronchiolitis to its use for hyper-
capnia rather than hypoxemia [19]. However, the bronchi-
olitis patients in our study received HFOV for hypoxemia or
hypoxemia and hypercapnia. Although 64 % of our patients
with bronchiolitis had underlying bronchopulmonary dys-
plasia, the overall survival rate was still 93 %. We made no
Table 4 Measures of oxygenation
Parameter Survived (n = 67) Died (n = 35) p value
OI
Baseline 25 (15) 33 (18.3) 0.32
0 h 30 (25) 44 (24.5) \0.01
4 h 22 (14.6) 33 (26) \0.01
12 h 16 (11) 31 (20) \0.001
24 h 15 (9.8) 27 (16) \0.001
72 h 12 (6.8) 27 (14.1) \0.01
Last day 10 (5.8) 51 (61) \0.001
Pa/FiO2
Baseline 76 (44.3) 66 (31.5) 0.4
0 h 72 (72.5) 60 (32.5) 0.03
4 h 115 (70) 85 (58) 0.02
12 h 131 (80.7) 87 (48) \0.001
24 h 164 (75.5) 92 (46) \0.001
72 h 166 (69.5) 100 (44) \0.001
Last day 172 (92) 54 (55) \0.001
Data are median and (IQR) or total number. Last day is the last day on
HFOV
Fig. 1 Comparison of oxygenation index of survivors and
nonsurvivors
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attempt to separate patients with RSV and HMPV bron-
chiolitis from those with the pneumonia. Most patients with
standard bronchiolitis during the study period were man-
aged with conventional ventilation and did not develop
AHRF. In our experience there is a spectrum of disease and
those who develop AHRF generally have bronchoalveolar
disease. Additionally, patients diagnosed with pneumonia
(viral or bacterial) who were treated with HFOV also had
statistically improved survival. Both of these groups of
patients showed early and sustained improvement in oxy-
genation when placed on HFOV. Our study supports the
idea that HFOV limits volutrauma in obstructive and alve-
olar lung disease, making these patients optimal candidates
for HFOV support. Limiting ventilator-induced lung injury,
as others have described with HFOV [20], may have also
played an important role in these patients.
The second major finding of our study is that a lack of
OI response to HFOV predicts mortality. Other pediatric
studies have also found that pulmonary-specific markers
(OI and FiO2/PaO2) are associated with mortality in
patients with AHRF [21–24]. Patients who did not show
improvement in OI in the first 12 h on HFOV did not
survive. Conversely, patients with sustained improvement
in oxygenation while on HFOV survived. An OI of[35 at
24 h predicted mortality with an OR of 31.11. This pre-
dictive OR is lower than previously reported values in
patients treated with HFOV [12]. Most mortality in our
PICU setting was due to circulatory failure or MODS
rather than hypoxemia. Nonetheless, a lower OI in the first
hours of HFOV support may portend improved survival.
Monitoring OI while utilizing HFOV is critical because
this formula includes a critical component of HFOV set-
tings, the Paw. It is clear that patients who respond to the
higher Paw generated by HFOV with sustained improve-
ment in PO2 are most likely to survive.
In this study, the use of an epinephrine infusion at the
time of HFOV initiation was associated with a mortality
OR of 2.75, which suggests that hemodynamically unstable
patients do worse than hemodynamically stable patients
when placed on HFOV. Subgroup analysis of survival of
patients with sepsis showed that the rate was slightly lower
than that of the overall group. Survivors in this subgroup
demonstrated improvement in oxygenation and metabolic
acidosis and required a lower dose of epinephrine within
4 h of going on HFOV. We suspect improvement in gas
exchange resulted in stabilization of MODS and hastened
resolution of circulatory failure. Previous work has also
shown that proinflammatory cytokines are reduced with
HFOV, so this may be a contributing factor [25].
Our study results raise unique questions about HFOV
therapy and reveal some study limitations. Some may
question the use of HFOV, which utilizes high intrathoracic
pressures and minimizes suctioning, in bronchiolitis. In
spite of this potential for thick secretions, small airway
obstruction, and air trapping, we found no difference in the
incidence of pneumothorax when comparing bronchiolitis
patients to patients with other diagnoses. We recognize that
ECMO criteria consider the OI and the Pa/FiO2 ratio when
selecting candidates and since our PICU was not an ECMO
center at the time of this study, a bias toward aggressive use
of HFOV may exist. Due to the retrospective nature of our
study, we chose to classify patients as having AHRF rather
than trying to assign each patient the diagnosis of ARDS.
Other studies have described the challenges and potential
errors in diagnosing ARDS [26–29]. Finally, we cannot say
with absolute certainty that the ventilation guidelines were
completely followed on each and every patient as this was
not a prospective study. However, our review of the respi-
ratory therapy charting suggested they were.
Conclusion
High-frequency oscillatory ventilation can be deployed for
pediatric AHRF of various etiologies with good overall
survival. Disease-specific morbidity associated with AHRF
appears to predict better survival rates on HFOV, particu-
larly favoring pulmonary disease states such as bronchi-
olitis and/or pneumonia. Early and sustained improvement
in OI predicts survival, and circulatory failure requiring
higher dosing of epinephrine in early HFOV predicts
increased mortality. Larger randomized controlled studies
are still needed to confirm optimal patient selection criteria
for HFOV.
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